• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    National Philanthropic Trust Welcomes Three Board Members

    1/3/24 9:30:00 AM ET
    $BANR
    $HLNE
    $OCGN
    Major Banks
    Finance
    Investment Managers
    Finance
    Get the next $BANR alert in real time by email

    Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth join the Board of Trustees at the largest national, independent donor-advised fund public charity

    National Philanthropic Trust (NPT), the largest national, independent public charity that manages donor-advised funds, and one of the leading grantmaking institutions in the U.S., is pleased to announce the appointment of Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth to its Board of Trustees.

    "As NPT continues to grow, innovate, and advance philanthropy around the world, we welcome these three accomplished professionals to our Board of Trustees," said Eileen Heisman, CEO of National Philanthropic Trust. "NPT is now the third largest grantmaking organization in the world. With esteemed careers in private market investing, technology, law, and philanthropy, Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth will make welcome additions to our board."

    Jeffrey Armbrister is an executive with more than 25 years of transaction-based investing and operational experience. He is the Chief Financial Officer of Hamilton Lane (NASDAQ:HLNE), a global private markets investment management firm.

    Armbrister previously served as the company's Global Head of Direct Equity Investments, where he was responsible for direction and oversight of the firm's direct equity and co-investment platform. His role included service on the boards of directors of companies in which Hamilton Lane invested on behalf of clients.

    Prior to joining Hamilton Lane, Armbrister served as Managing Director for Versa Capital Management, where he focused on making control-oriented, special situations, debt and equity investments in middle market companies across a variety of industries. While at Versa, he participated in all major investment functions, providing oversight for certain finance-related operational activities, including financial analysis and reporting and cash flow management for several portfolio companies.

    Prior to joining Versa, Armbrister was an Equity Research analyst at Oppenheimer + Close. He has also held private equity, venture capital, corporate development, and investment banking positions at Berwind Financial Group, Redleaf Group, ICG Commerce, and Wheat First Butcher Singer, respectively. He currently serves on the board of directors or similar bodies of several charitable organizations. Armbrister received his Bachelor of Arts in Economics from the University of Virginia.

    Lindy Benton-Moreno, an accomplished leader and sought-after speaker, has devoted her 30-year healthcare IT career to advancing technology and inspiring leaders. As an Executive Board Chair of Vyne, Benton-Moreno fueled the growth of a small dental company by establishing a thriving medical division.

    She was named by Health Data Management among the "Most Powerful Women in Healthcare IT" and recognized on Becker's "Women Power Players Health IT" list. As a Fellow at the Health Information and Management Systems Society, she engages with executive councils across health-related committees and industry associations.

    With a Master of Science from Florida State University, Benton-Moreno became a Distinguished Alumnus in Business and Industry, serving on the university's National Board of Directors as the university Alumni Association's National Director. Prior to entering healthcare IT, she pioneered the mainstreaming of 100+ children with disabilities into Florida's public schools and the sponsoring of scholarships for first-generation college students, an initiative close to her heart.

    Connie Collingsworth is an experienced board member with expertise in governance, risk management, executive compensation, and complex investments for publicly traded companies, private companies, and private equity funds. Her board experience includes leadership positions on public and private company boards as well as charitable organizations.

    Collingsworth's current board roles include Banner Corporation (NASDAQ:BANR) and Axxes Capital. She also serves as a Board Advisor to European private equity fund Planet First Partners, a Business Advisory Board Member to biotech company Ocugen (NASDAQ:OCGN), and a Strategic Advisor to venture fund LoudCapital.

    Collingsworth is the former Chief Operating Officer of the Bill & Melinda Gates Foundation, the largest private foundation in the world with over $65 billion in assets, distributing over $8.3 billion annually. During her 22-year tenure, she was responsible for managing and scaling the foundation's business operations globally. She also served as Chief Legal Officer, advising Bill Gates, Melinda French Gates, and Warren Buffett on governance, including creating the foundation's Governing Board. She was the architect of the foundation's IP philosophy and led the foundation's work in collaborating with for-profit companies, including big pharma and companies in the biotech and ed-tech sectors.

    Collingsworth holds a Master of Laws in International Business Studies from the University of Exeter, England, a Juris Doctorate from the University of Nebraska, and a Bachelor of Arts from Andrews University.

    About National Philanthropic Trust

    Founded in 1996, National Philanthropic Trust (NPT) is the largest national, independent public charity that manages donor-advised funds and one of the leading grantmaking institutions in the U.S. Since its founding, NPT has raised more than $49.8 billion in charitable funding and has made more than 640,000 grants exceeding $25.7 billion to nonprofits around the world. NPT annually publishes the Donor-Advised Fund Report, the sector's authority on the state of DAF philanthropy. Visit NPT's resource library to learn what you can do with a DAF and about NPT's impact investing options. More at NPTrust.org and NPTGivingPoint.org.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240103652385/en/

    Get the next $BANR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BANR
    $HLNE
    $OCGN

    CompanyDatePrice TargetRatingAnalyst
    Hamilton Lane Incorporated
    $HLNE
    5/15/2025Outperform → Perform
    Oppenheimer
    Banner Corporation
    $BANR
    4/21/2025$71.00Neutral → Buy
    Janney
    Hamilton Lane Incorporated
    $HLNE
    1/21/2025$186.00Perform → Outperform
    Oppenheimer
    Hamilton Lane Incorporated
    $HLNE
    1/6/2025$139.00Neutral → Sell
    Goldman
    Ocugen Inc.
    $OCGN
    10/15/2024$4.00Buy
    Maxim Group
    Hamilton Lane Incorporated
    $HLNE
    9/12/2024$156.00Equal Weight
    Wells Fargo
    Banner Corporation
    $BANR
    7/19/2024Buy → Neutral
    Janney
    Hamilton Lane Incorporated
    $HLNE
    4/11/2024$115.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $BANR
    $HLNE
    $OCGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hamilton Lane downgraded by Oppenheimer

      Oppenheimer downgraded Hamilton Lane from Outperform to Perform

      5/15/25 8:08:14 AM ET
      $HLNE
      Investment Managers
      Finance
    • Banner upgraded by Janney with a new price target

      Janney upgraded Banner from Neutral to Buy and set a new price target of $71.00

      4/21/25 8:28:02 AM ET
      $BANR
      Major Banks
      Finance
    • Hamilton Lane upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Hamilton Lane from Perform to Outperform and set a new price target of $186.00

      1/21/25 7:49:57 AM ET
      $HLNE
      Investment Managers
      Finance

    $BANR
    $HLNE
    $OCGN
    SEC Filings

    See more
    • Banner Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BANNER CORP (0000946673) (Filer)

      7/24/25 5:02:11 PM ET
      $BANR
      Major Banks
      Finance
    • SEC Form DEFA14A filed by Hamilton Lane Incorporated

      DEFA14A - Hamilton Lane INC (0001433642) (Filer)

      7/24/25 4:17:30 PM ET
      $HLNE
      Investment Managers
      Finance
    • SEC Form DEF 14A filed by Hamilton Lane Incorporated

      DEF 14A - Hamilton Lane INC (0001433642) (Filer)

      7/24/25 4:14:37 PM ET
      $HLNE
      Investment Managers
      Finance

    $BANR
    $HLNE
    $OCGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      12/2/24 4:15:25 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      11/26/24 4:50:10 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Co-Chief Executive Officer Delgado-Moreira Juan bought $105,950 worth of shares (525 units at $201.81) (SEC Form 4)

      4 - Hamilton Lane INC (0001433642) (Issuer)

      11/13/24 4:31:06 PM ET
      $HLNE
      Investment Managers
      Finance

    $BANR
    $HLNE
    $OCGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 3 filed by new insider Chandrasekhar Satishchandran

      3/A - Ocugen, Inc. (0001372299) (Issuer)

      6/12/25 4:28:45 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Chandrasekhar Satishchandran

      4 - Ocugen, Inc. (0001372299) (Issuer)

      6/9/25 5:19:37 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Coleman Blaise

      4 - Ocugen, Inc. (0001372299) (Issuer)

      6/9/25 5:19:31 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BANR
    $HLNE
    $OCGN
    Financials

    Live finance-specific insights

    See more
    • Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

      MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, August 1, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 9627149Webcast: Available on the events section of the

      7/17/25 6:30:16 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Banner Corporation Reports Net Income of $45.5 Million, or $1.31 Per Diluted Share, for Second Quarter 2025; Declares Quarterly Cash Dividend of $0.48 Per Share

      Banner Corporation (NASDAQ:BANR) ("Banner"), the parent company of Banner Bank, today reported net income of $45.5 million, or $1.31 per diluted share, for the second quarter of 2025, compared to $45.1 million, or $1.30 per diluted share, for the preceding quarter and $39.8 million, or $1.15 per diluted share, for the second quarter of 2024. Net interest income was $144.4 million for the second quarter of 2025, compared to $141.1 million in the preceding quarter and $132.5 million for the second quarter a year ago. The increase in net interest income compared to the preceding quarter reflects an increase in both the yield and average balance of interest-earning assets, partially offset by a

      7/16/25 4:00:00 PM ET
      $BANR
      Major Banks
      Finance
    • Hamilton Lane Incorporated to Announce First Quarter Fiscal 2026 Results on August 5, 2025

      CONSHOHOCKEN, Pa., July 15, 2025 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the first fiscal quarter ended June 30, 2025 before the market opens on Tuesday, August 5, 2025. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website at https://shareholders.hamiltonlane.com/. Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on August 5 to discuss the results for the first fiscal quarter. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here (https://shareholders.hamiltonlane.com/) at least 15 minut

      7/15/25 7:00:00 AM ET
      $HLNE
      Investment Managers
      Finance

    $BANR
    $HLNE
    $OCGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

      SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

      11/13/24 9:56:40 PM ET
      $HLNE
      Investment Managers
      Finance
    • Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      11/12/24 4:59:47 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

      SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

      11/12/24 3:55:46 PM ET
      $HLNE
      Investment Managers
      Finance

    $BANR
    $HLNE
    $OCGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Banner Corporation Announces Stock Repurchase Program

      Banner Corporation (NASDAQ:BANR) ("Company"), the parent company of Banner Bank, today announced that its Board of Directors has authorized the repurchase of up to 1,729,199 shares of the Company's common stock, which is approximately 5% of its issued and outstanding common stock. "We view our stock to be a compelling investment opportunity, and believe that repurchasing shares supports the creation of long-term shareholder value," said Mark J. Grescovich, President and Chief Executive Officer. Under the repurchase program, shares may be repurchased by the Company in open market purchases. The extent to which the Company repurchases its shares and the timing of such repurchases will depen

      7/24/25 4:00:00 PM ET
      $BANR
      Major Banks
      Finance
    • Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

      MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced updates to its Retina Scientific Advisory Board (SAB) and Executive Leadership Team to enhance external guidance from key opinion leaders and strengthen the Company's internal expertise in critical functions and as it pursues its goal of three BLAs in the next three years. "As our novel modifier gene therapy programs continue to progress and demonstrate positive data in the clinic, it is now more important than ever to solidify an optimized Retina SAB reflecting the absolute best guidance in this spa

      7/21/25 7:30:00 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

      MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). "Dosing the first patient is an especially significant milestone and brings us closer to our goal of addressing the unmet medical need that exists for all Stargardt patients—100,000 in the U.S. and Europe and 1 million worldwide," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of

      7/18/25 7:02:00 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BANR
    $HLNE
    $OCGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Cosette Pharmaceuticals Appoints Jeff Neubig as Vice President, Quality and Regulatory Affairs

      -- Experienced Industry Leader to drive Cosette's Best-in-Class Quality Organization and facilitate Regulatory Approvals -- Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630266171/en/Jeff Neubig, VP, Quality & Regulatory Affairs, Cosette Pharmaceuticals In this critical role, Jeff will lead Cosette's best-in-class quality and regulatory affairs organizations, maintaining the company's rigorous quality standards and further establishing Co

      6/30/25 8:00:00 AM ET
      $HLNE
      Investment Managers
      Finance
    • Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

      Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova's board, and the successful completion of a new round of growth equity capital. These developments support Grenova's strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company's future. "I

      4/23/25 8:00:00 AM ET
      $HLNE
      Investment Managers
      Finance
    • Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations

      Industry leader with 35+ years of experience in manufacturing operations and global supply chain excellence Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette's manufacturing, global supply chain, and operational strategy, ensuring efficiency, and supply continuity as the company continues its strong trajectory of growth and transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210366017/en/Senior Vice President, Operations (Photo

      2/10/25 8:00:00 AM ET
      $HLNE
      Investment Managers
      Finance